Find a Trial
Trial Summary
| Protocol No. | S1701 | ||
|---|---|---|---|
| Status | OPEN TO ACCRUAL | ||
| Principal Investigator | Loehrer, Patrick | ||
| Scope | National | ||
| Phase | Phase II | ||
| Age Group | Adult | ||
| Title | A RANDOMIZED PHASE II TRIAL OF CARBOPLATIN-PACLITAXEL WITH OR WITHOUT RAMUCIRUMAB IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED, RECURRENT, OR METASTATIC THYMIC CARCINOMA | ||
| Description | This randomized phase II trial studies how well carboplatin and paclitaxel with or without ramucirumab work in treating patients with thymic cancer that has spread to other places in the body, has come back, or cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as ramucirumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known if giving carboplatin and paclitaxel with or without ramucirumab will work better in treating patients with thymic cancer. | ||
| Key Eligibility | In order to be eligible to take part in this trial, patients must meet the following criteria:
| ||
| Applicable Disease Sites | Other Respiratory and Intrathoracic Organs | ||
| Participating Institutions | Indiana University (IU) | ||
| Treatment Type | Treatment | ||
| Contact | Phone: (317) 278-5632 Email: iutrials@iu.edu | ||